NCT01452477

Effect of Tanshinone on Hormonal and Metabolic Features in Women With Polycystic Ovary Syndrome (PCOS)

Status unknown NA Last updated 3 September 2013

What this trial tests

NA trial testing tanshinone in Polycystic Ovary Syndrome in 100 participants. Status unknown.

Timeline

1 October 2011

Primary endpoint
1 December 2013

1 July 2014

Quick facts

Lead sponsor	Heilongjiang University of Chinese Medicine
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	100
Start date	1 October 2011
Primary completion	1 December 2013
Estimated completion	1 July 2014
Sites	4 locations across China

Drugs / interventions tested

• tanshinone — full drug profile →
• tanshinone placebo

Conditions studied

• Polycystic Ovary Syndrome — all drugs for Polycystic Ovary Syndrome →

Sponsor

Heilongjiang University of Chinese Medicine

Who can join

Adults 18 to 36, female only, with Polycystic Ovary Syndrome. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

• basal testosterone
  Time frame: 3 months
  The primary outcome measure is a decrease in basal testosterone.

Sponsor's own description

Tanshinone was originally isolated from dried roots of Salvia miltiorrhiza bunge. In Chinese medicine, this herb has been widely prescribed for several pathologies, including diabetes, acne, cardiovascular disease.It has been demonstrated that the therapeutic benefit of cryptotanshinone on prenatally androgenized rats may be mediated by its dual regulation of key molecules during both insulin signaling and androgen synthesis.The purpose of this study is to determine whether tanshinone may prove effective in eradicating Polycystic Ovary Syndrome (PCOS) symptomatology.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

1. Tanshinone I activates the Nrf2-dependent antioxidant response and protects against As(III)-induced lung inflammation in vitro and in vivo.
   Tao S, Zheng Y, Lau A, Jaramillo MC, et al · · 2013 · cited 80× · PMID 23394605 · DOI 10.1089/ars.2012.5117
2. Ferroptosis-modulating small molecules for targeting drug-resistant cancer: Challenges and opportunities in manipulating redox signaling.
   Koeberle SC, Kipp AP, Stuppner H, Koeberle A. · · 2023 · cited 74× · PMID 36658724 · DOI 10.1002/med.21933
3. Targeting the Ubiquitin-Proteasome System and Recent Advances in Cancer Therapy.
   Spano D, Catara G. · · 2023 · cited 49× · PMID 38201233 · DOI 10.3390/cells13010029
4. The Skeletal Effects of Tanshinones: A Review.
   Ekeuku SO, Pang KL, Chin KY. · · 2021 · cited 14× · PMID 33923673 · DOI 10.3390/molecules26082319
5. Aurora kinases signaling in cancer: from molecular perception to targeted therapies.
   Vats P, Saini C, Baweja B, Srivastava SK, et al · · 2025 · cited 6× · PMID 40533769 · DOI 10.1186/s12943-025-02353-3
6. Natural Metabolites as Modulators of Sensing and Signaling Mechanisms: Unlocking Anti-Ovarian Cancer Potential.
   Verma M, Mishra PS, Rahaman SKA, Gupta T, et al · · 2025 · cited 1× · PMID 40868085 · DOI 10.3390/biomedicines13081830
7. Computational drug screening against the SARS-CoV-2 Saudi Arabia isolates through a multiple-sequence alignment approach.
   Mok PL, Koh AE, Farhana A, Alsrhani A, et al · · 2021 · PMID 33551661 · DOI 10.1016/j.sjbs.2021.01.051